Schrodinger Inc. (SDGR) News
Filter SDGR News Items
SDGR News Results
| Date | Symbol | Company | Title | Start | End | Change | POWR Rating | ||
|---|---|---|---|---|---|---|---|---|---|
| Loading, please wait... | |||||||||
SDGR News Highlights
- For SDGR, its 30 day story count is now at 5.
- Over the past 13 days, the trend for SDGR's stories per day has been choppy and unclear. It has oscillated between 1 and 1.
- DRUG are the most mentioned tickers in articles about SDGR.
Latest SDGR News From Around the Web
Below are the latest news stories about SCHRODINGER INC that investors may wish to consider to help them evaluate SDGR as an investment opportunity.
Schrödinger Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)NEW YORK, December 19, 2023--Schrödinger, Inc. (Nasdaq: SDGR), whose physics-based computational platform is transforming the way therapeutics and materials are discovered, today reported that on December 13, 2023, the company granted (i) non-statutory stock options to purchase 1,800 shares of the company’s common stock to three newly hired employees and (ii) restricted stock units (RSUs) with respect to 2,250 shares of the company’s common stock to three newly hired employees. These grants were |
Schrödinger Highlights Progress of Clinical Programs and Discloses Three New Programs at First Therapeutics Pipeline Investor EventNEW YORK, December 14, 2023--Schrödinger is providing a detailed review of its proprietary drug discovery and development programs during its Pipeline Day. |
Artificial Intelligence in Healthcare: 3 Stocks Transforming the IndustryCompanies are applying AI in healthcare which is leading to better outcomes and stronger performance for their stocks. |
Schrödinger Presents Data Supporting Advancement of SGR-1505 and SGR-2921 at American Society of Hematology 2023 Annual MeetingNEW YORK, December 10, 2023--Schrödinger today announced new preclinical data on SGR-1505, its investigational MALT1 inhibitor, and SGR-2921, its investigational CDC7 inhibitor. |
Micro/Small Cap Companies Using AI In Drug Discovery Up 35% In NovemberThe AI method is up to 250 times more efficient than the traditional method of drug discovery. reducing timelines for drug discovery, increasing accuracy of efficacy and safety predictions. |
3 Cutting-Edge Biotech Stocks for the Bold InvestorAhead of what could be significant uncertainties in the market, investors may be better served with cutting-edge biotech stocks. |
AI Alert: 3 Healthcare Stocks That Are Investing in Artificial IntelligenceWe’re still in the initial stages of a massively disruptive artificial intelligence (AI) boom that's greatly impacting healthcare. |
Schrödinger to Participate in Upcoming Investor ConferencesNEW YORK, November 06, 2023--Schrödinger today announced that management will participate in two conferences in November. |
3 Top Publicly Traded Companies Leading the AI RevolutionWith recent data indicating AI is saving companies loads of money, three AI stocks to buy are exploiting this trend. |
Schrödinger, Inc. (NASDAQ:SDGR) Q3 2023 Earnings Call TranscriptSchrödinger, Inc. (NASDAQ:SDGR) Q3 2023 Earnings Call Transcript November 1, 2023 Schrödinger, Inc. misses on earnings expectations. Reported EPS is $-0.86 EPS, expectations were $-0.69. Operator: Welcome to Schrödinger’s Conference Call to review Third Quarter 2023 Financial Results. My name is Eric and I will be your operator for today’s call. All lines have been […] |